Gynecologic Cancers

BRCA+

Questions discussed in this category

In the absence of a cohesive workflow guiding the use of PARPi in ovarian cancer since the 2022 FDA approval withdrawals, what is your general approach to PARPi usage in the front-line and recurrent setting?

1 Answer available

Given more restrictions on later line PARP inhibitor use for patients by BRCA status, would you consider repeat biopsy with somatic testing to identify candidates for second line maintenance therapy following platinum treatment for a patient who is gBRCAwt?

Does your approach change depending on the patients initial somatic BRCA status?

2 Answers available

How do you counsel premenopausal women with BRCA1 or BRCA2 mutations on the need for bilateral oopherectomy?

2 Answers available

What factors impact your decision to include bevacizumab with primary chemotherapy for patients with BRCA+ or HRD+ ovarian cancer?

Does your practice vary based on risk status (low vs high risk) or specific mutation status (BRCA+ vs HRD+) given PAOLA subset analyses?

4 Answers available

Which PARP inhibitor do you recommend for maintenance therapy in BRCA+ ovarian cancer after primary chemotherapy and why?

How do the 5 year results of SOLO-1 at ESMO 2020 impact your recommendations?

3 Answers available

How do you advise patients on duration of first line maintenance PARPi and the potential risk of MDS or AML?

Is MDS/AML risk increased with longer duration of therapy? Does your approach differ for patients who are BRCA+/HRD vs wild type/HRP?

2 Answers available

Papers discussed in this category

The New England journal of medicine, 2018-12-27

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Lancet Oncol, 2021 Mar 18

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.

N Engl J Med, 2019 Dec 19

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-09-10

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

Lancet Oncol, 2015 Jun 23

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

Lancet (London, England), 2017-10-28

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

The New England journal of medicine, 2016-12-01

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

The New England journal of medicine, 2012-04-12

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

N. Engl. J. Med., 2019 Sep 28

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Sep 09

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.

Related Topics in Gynecologic Cancers